NCT03816163 2026-03-12
A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer
Astellas Pharma Inc
Phase 2 Active not recruiting
Clinical Trials
13 trialsNCT06901531 2026-03-11
LUCERNA
Astellas Pharma Inc
Phase 3 Recruiting
NCT07431281 2026-02-24
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
AstraZeneca
Phase 3 Recruiting
NCT03504397 2026-02-13
Spotlight
Astellas Pharma Inc
Phase 3 Active not recruiting
NCT03653507 2026-02-06
GLOW
Astellas Pharma Inc
Phase 3 Active not recruiting
NCT06396091 2025-11-13
A Study of Zolbetuximab With Chemotherapy in Adults With Pancreatic Cancer
Astellas Pharma Inc
Phase 1 Active not recruiting
NCT03505320 2025-10-20
ILUSTRO
Astellas Pharma Inc
Phase 2 Active not recruiting
NCT01630083 2025-06-15
FAST
Astellas Pharma Inc
Phase 2 Completed
NCT01197885 2025-06-13
Efficacy and Safety Study of Multiple Doses of IMAB362 in Patients With Advanced Gastroesophageal Cancer
Astellas Pharma Inc
Phase 2 Completed
NCT03528629 2024-12-02
A Study of IMAB362 in Japanese Subjects With Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma
Astellas Pharma Inc
Phase NA Completed
NCT00909025 2024-11-21
Safety and Tolerability Study of Claudiximab in Patients With Advanced Gastroesophageal Cancer
Astellas Pharma Inc
Phase 1 Completed
NCT04086758 2024-11-20
A Pharmacokinetic Study of Zolbetuximab (IMAB362) in Chinese Subjects With Locally Advanced Unresectable or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma
Astellas Pharma Inc
Phase 1 Completed
NCT01671774 2024-11-14
PILOT
Astellas Pharma Inc
Phase 1 Completed